How to Decide Against Aripiprazole in Overweight TRD Patients
When should clinicians avoid aripiprazole augmentation in treatment-resistant depression because harms outweigh benefits?
Aripiprazole augmentation can improve depressive symptoms in treatment-resistant depression, but its added benefit may be offset by long-term adverse effects that matter differently across patients. This guide applies when clinicians are considering aripiprazole versus bupropion-based strategies and need to identify patients, especially those with elevated baseline BMI, in whom aripiprazole ranked poorly in the article's model.
-
Assess baseline BMI before offering aripiprazole augmentation
Check whether the patient has elevated baseline BMI, defined in the model as 25 or greater. This was the key subgroup characteristic that made aripiprazole the least preferred of the three strategies once long-term harms were incorporated.
-
Compare aripiprazole with switching to bupropion differently by weight category
Among patients with nonelevated weight, aripiprazole was preferred over switching to bupropion. Among patients who were overweight at baseline, switching to bupropion was preferred over aripiprazole because side effects outweighed aripiprazole's added antidepressant benefit.
-
Quantify the limited efficacy advantage of aripiprazole
In adults under 65 years, aripiprazole provided 27.3 additional gross depression-free day equivalents compared with switching to bupropion. The article also notes that aripiprazole's additional efficacy over bupropion augmentation was small, roughly equivalent to about 1 week earlier remission of depressive symptoms.
-
Factor tardive dyskinesia into the decision every time aripiprazole is considered
The model treated tardive dyskinesia as specific to aripiprazole augmentation and long-lasting. Its harms offset 56% to 81% of aripiprazole's depression benefit over switching to bupropion, amounting to an expected quality-of-life loss equivalent to about 2 to 3 weeks of additional depressive symptoms.
-
Give extra weight to metabolic harm in patients who are already overweight
In patients with elevated baseline BMI, weight-related side effects of aripiprazole relative to switching to bupropion were 95% to 131% as large as the depression benefit of aripiprazole. The article concludes that, in overweight adults, the expected lifetime harms from weight gain were about as large as the depression benefit relative to switching to bupropion.
-
Prefer bupropion augmentation over aripiprazole for most adults
Across almost all subgroups, combination bupropion offered a better balance of effectiveness and tolerability than aripiprazole. The only base-case exception was adults aged 85 to 89 years with nonelevated weight, in whom aripiprazole ranked higher because falls weighed more heavily against combination bupropion.
-
Use shared decision-making when aripiprazole remains under consideration
Present aripiprazole as a tradeoff between modest additional antidepressant benefit and potentially insidious long-term risks, especially tardive dyskinesia and weight gain. The article explicitly frames its results as a starting point for shared decision-making because balancing short-term benefit against long-term harm is challenging for both clinicians and patients.
Clinical Considerations
- The weight-gain analysis in the base case focused on patients with elevated baseline BMI, although a sensitivity analysis allowing weight-related harms in some nonelevated-weight patients slightly reduced aripiprazole's advantage in the oldest nonelevated-weight subgroup.
- The model did not include all adverse effects of aripiprazole, including akathisia, insomnia, and other acute extrapyramidal symptoms.
- The findings are based on modeled long-term consequences rather than direct long-term comparative trials of all outcomes.
- Individual patients may respond better or worse than the average values used in the model and may value specific outcomes differently.
Bottom Line
Avoid making aripiprazole augmentation the default next step in treatment-resistant depression when baseline BMI is elevated, because in this model its weight-gain and tardive dyskinesia harms outweighed its modest efficacy advantage.
